case_images: PMC7411254_01
case_images: PMC7411254_02
case_images: The reads of 20 insertion subtypes identified by NGS and Sanger sequencing. (A,C) Patient 4 with G780_P781dupGSP; (B,D) Patient 5 with G778_S779insCPG.
case_images: fonc-10-01162-g0001.jpg
case_images: PMC7411254_03_fonc-10-01162-g0001.jpg
case_images: F1
case_images: The result of NGS revealed HER2 insertion mutation (p.G780_P781dupGSP) (Figures 1B,D).
case_images: Representative images from chest CT.
case_images: fonc-10-01162-g0002.jpg
case_images: PMC7411254_03_fonc-10-01162-g0002.jpg
case_images: F2
case_images: Then the patient took pyrotinib as the third-line therapy with the best response of PR, and PFS was 12.5 months until November 30, 2019 (Figure 2).
case_images: PMC7411254_03
case_images: The reads of 20 insertion subtypes identified by NGS and Sanger sequencing. (A,C) Patient 4 with G780_P781dupGSP; (B,D) Patient 5 with G778_S779insCPG.
case_images: fonc-10-01162-g0001.jpg
case_images: PMC7411254_03_fonc-10-01162-g0001.jpg
case_images: F1
case_images: The result of NGS revealed HER2 insertion mutation (p.G780_P781dupGSP) (Figures 1B,D).
case_images: Representative images from chest CT.
case_images: fonc-10-01162-g0002.jpg
case_images: PMC7411254_03_fonc-10-01162-g0002.jpg
case_images: F2
case_images: Then the patient took pyrotinib as the third-line therapy with the best response of PR, and PFS was 12.5 months until November 30, 2019 (Figure 2).